A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial - Report - MDSpire

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial

This is a randomized, phase 3, multicenter trial designed to determine if induction weekly chemotherapy, when added to standard concurrent chemoradiotherapy and immunotherapy, for locally advanced cervical cancers can improve disease control and cure rate. The outcome for this study will be assessed over the first 2-3 years following completion of the therapy to which the patient is randomized. 

  • By

  • July 26, 2026

  • 3 min

Share

Clinical Report: A Phase III Study of Induction Pembrolizumab and Chemotherapy

Overview

This phase III trial investigates the efficacy of induction chemotherapy combined with pembrolizumab followed by chemoradiation in patients with high-risk locally advanced cervical cancer.

Background

Locally advanced cervical cancer (LACC) remains a significant clinical challenge, with suboptimal outcomes despite standard concurrent chemoradiation therapy. Understanding the potential benefits of integrating immunotherapy and induction chemotherapy prior to chemoradiation is important.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • The trial is designed to assess the impact of induction chemotherapy on disease control in LACC.
  • Patients must have pathologically confirmed newly diagnosed cervical cancer with specific staging criteria.
  • Exploratory analyses will include immune and molecular biomarkers associated with treatment response.

Clinical Implications

The findings from this trial may provide insights into the effectiveness of combining induction chemotherapy with immunotherapy for LACC.

Conclusion

This study aims to clarify the role of induction chemotherapy and immunotherapy in improving outcomes for patients with high-risk locally advanced cervical cancer.

Related Resources & Content

  1. FDA, FDA, 2024 -- FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer
  2. Lorusso et al, PubMed, 2024 -- Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer
  3. McCormack et al, The ASCO Post, 2024 -- Addition of Induction Chemotherapy to Standard Chemoradiotherapy in Locally Advanced Cervical Cancer KEY POINTS
  4. the asco post — Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
  5. the asco post — Overall Survival Results With Pembrolizumab and Chemoradiotherapy in Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
  6. roswell park comprehensive cancer center — Can Induction Improve Survival in High-Risk, Locally Advanced Cervical Cancer?
  7. Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
  8. Overall Survival Results With Pembrolizumab and Chemoradiotherapy in Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
  9. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer | FDA
  10. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial - PubMed
  11. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial

Original Source(s)

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial

  • by

  • July 26, 2026

Related Content

Editorial: Navigating the landscape of IDH-mutant gliomas: advances in diagnosis, therapeutic management, and long-term monitoring

Case Report: Evolution of intratumoral spatial heterogeneity assessed by [68Ga]Ga-DOTA-NOC PET/CT during dinutuximab beta therapy in pediatric high-risk neuroblastoma

Circadian rhythms in the tumor microenvironment: spatiotemporal immune regulation and chronotherapeutic opportunities